March 6, 2019 02:43 PM EST

From dinner in Munich to $5.85 a share, Immune Design execs pushed for every penny they could get from the Merck bargain buyout

John Carroll

Editor & Founder

October 11, 2018 was Black Thursday at Immune Design $IMDZ. That’s when the company broadcast that its lead program for CMB305 combined with Roche’s Tecentriq …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

From dinner in Munich to $5.85 a share, Immune Design execs pushed for every penny they could get from the Merck bargain buyout

John Carroll

Editor & Founder

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Lack of detail in Trump's drug price plan raises more questions than answers

Updated: White House threatens ‘most favored nation’ plan to lower US drug prices, but many questions remain

Roche could rethink $50B US expansion plan if new policies 'harm' operations

Pharma investors brush off Trump’s ‘most favored nation’ plan as stocks rise

Exclusive: Patrick Hsu startup launches, looks beyond CRISPR for gene insertion technology

PBM overhaul and drug price negotiations make the cut in Republicans' tax bill

From din­ner in Mu­nich to $5.85 a share, Im­mune De­sign ex­ecs pushed for every pen­ny they could get from the Mer­ck bar­gain buy­out

Editor & Founder

Sign up to read this article for free.

more like this

Celldex Therapeutics

Hampton, NJ, USA

From dinner in Munich to $5.85 a share, Immune Design execs pushed for every penny they could get from the Merck bargain buyout